Clinical and genetic correlates of circulating angiopoietin-2 and soluble tie-2 in the community

Circulation: Cardiovascular Genetics

Volumn 3, Issue 3, 2010, Pages 300-306

  Lieb, Wolfgang ^a   Zachariah, Justin P ^a,b,c   Xanthakis, Vanessa ^f   Safa, Radwan ^g   Chen, Ming Huei ^g   Sullivan, Lisa M ^f   Larson, Martin G ^a,h   Smith, Holly M ^d   Yang, Qiong ^f   Mitchell, Gary F ^e   Vita, Joseph A ^g   Sawyer, Douglas B ^d   Vasan, Ramachandran S ^a,g  

^a FRAMINGHAM HEART STUDY   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d VANDERBILT UNIVERSITY   (United States)

^e CARDIOVASCULAR ENGINEERING INC   (United States)

^f BOSTON UNIVERSITY   (United States)

^g BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h Boston University   (United States)

Author keywords

Angiopoietins; CVD risk factors; Epidemiology; Growth substances; Heritability; Metabolic syndrome; Vascular remodeling

Indexed keywords

ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; CHOLESTEROL; TRIACYLGLYCEROL; BIOLOGICAL MARKER;

ADULT; AGE; ALCOHOL CONSUMPTION; ANGIOGENESIS; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHROMOSOME 9; COHORT ANALYSIS; COMMUNITY ASSESSMENT; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DYSLIPIDEMIA; FEMALE; GENETIC CORRELATION; GENETIC TRAIT; GLOMERULUS FILTRATION RATE; HERITABILITY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEX DIFFERENCE; SMOKING; SYSTOLIC BLOOD PRESSURE; TISSUE REPAIR; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DYSLIPIDEMIAS; GENETIC LINKAGE; GENETICS; MIDDLE AGED; RISK FACTOR;

ADULT; ANGIOPOIETIN-2; BIOLOGICAL MARKERS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; COHORT STUDIES; DYSLIPIDEMIAS; FEMALE; GENETIC LINKAGE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; RECEPTOR, TIE-2; RISK FACTORS;

EID: 77955903020     PISSN: 1942325X     EISSN: 19423268     Source Type: Journal    
DOI: 10.1161/CIRCGENETICS.109.914556     Document Type: Article

References (44)

1. Gibbons GH, Dzau VJ. The emerging concept of vascular remodeling. N Engl J Med. 1994;330:1431-1438.
2. Ward NL, Dumont DJ. The angiopoietins and Tie2/Tek: adding to the complexity of cardiovascular development. Semin Cell Dev Biol. 2002; 13:19-27.
3. Sato TN, Tozawa Y, Deutsch U, Wolburg-Buchholz K, Fujiwara Y, Gendron-Maguire M, Gridley T, Wolburg H, Risau W, Qin Y. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature. 1995;376:70-74.
4. Eklund L, Olsen BR. Tie receptors and their angiopoietin ligands are context-dependent regulators of vascular remodeling. Exp Cell Res. 2006; 312:630-641.
5. Fiedler U, Augustin HG. Angiopoietins: a link between angiogenesis and inflammation. Trends Immunol. 2006;27:552-558.
6. Asahara T, Chen D, Takahashi T, Fujikawa K, Kearney M, Magner M, Yancopoulos GD, Isner JM. Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization. Circ Res. 1998;83:233-240.
7. Peters KG. Vascular endothelial growth factor and the angiopoietins: working together to build a better blood vessel. Circ Res. 1998;83: 342-343.
8. Reusch P, Barleon B, Weindel K, Martiny-Baron G, Godde A, Siemeister G, Marme D. Identification of a soluble form of the angiopoietin receptor TIE-2 released from endothelial cells and present in human blood. Angiogenesis. 2001;4:123-131.
9. Findley CM, Mitchell RG, Duscha BD, Annex BH, Kontos CD. Plasma levels of soluble Tie2 and vascular endothelial growth factor distinguish critical limb ischemia from intermittent claudication in patients with peripheral arterial disease. J Am Coll Cardiol. 2008;52:387-393.
10. Lee KW, Lip GY, Blann AD. Plasma angiopoietin-1, angiopoietin-2, angiopoietin receptor tie-2, and vascular endothelial growth factor levels in acute coronary syndromes. Circulation. 2004;110:2355-2360.
11. Chong AY, Caine GJ, Freestone B, Blann AD, Lip GY. Plasma angiopoietin-1, angiopoietin-2, and angiopoietin receptor tie-2 levels in congestive heart failure. J Am Coll Cardiol. 2004;43:423-428.
12. Patel JV, Lim HS, Varughese GI, Hughes EA, Lip GY. Angiopoietin-2 levels as a biomarker of cardiovascular risk in patients with hypertension. Ann Med. 2008;40:215-222.
13. Patel JV, Abraheem A, Chackathayil J, Gunning M, Creamer J, Hughes EA, Lip GY. Circulating biomarkers of angiogenesis as indicators of left ventricular systolic dysfunction amongst patients with coronary artery disease. J Intern Med. 2009;265:562-567.
14. Nadar SK, Blann A, Beevers DG, Lip GY. Abnormal angiopoietins 1&2, angiopoietin receptor Tie-2 and vascular endothelial growth factor levels in hypertension: relationship to target organ damage [a sub-study of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)]. J Intern Med. 2005;258:336-343.
15. Splansky GL, Corey D, Yang Q, Atwood LD, Cupples LA, Benjamin EJ, D Agostino RB Sr, Fox CS, Larson MG, Murabito JM, O Donnell CJ, Vasan RS, Wolf PA, Levy D. The Third Generation Cohort of the National Heart, Lung, and Blood Institute's Framingham Heart Study: design, recruitment, and initial examination. Am J Epidemiol. 2007;165: 1328-1335.
16. Lieb W, Safa R, Benjamin EJ, Xanthakis V, Yin X, Sullivan LM, Larson MG, Smith HM, Vita JA, Mitchell GF, Sawyer DB, Vasan RS. Vascular endothelial growth factor, its soluble receptor, and hepatocyte growth factor: clinical and genetic correlates and association with vascular function. Eur Heart J. 2009;30:1121-1127.
17. Levy D, Labib SB, Anderson KM, Christiansen JC, Kannel WB, Castelli WP. Determinants of sensitivity and specificity of electrocardiographic criteria for left ventricular hypertrophy. Circulation. 1990;81:815-820.
18. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735-2752.
19. Khalil RA. Sex hormones as potential modulators of vascular function in hypertension. Hypertension. 2005;46:249-254.
20. Silha JV, Krsek M, Sucharda P, Murphy LJ. Angiogenic factors are elevated in overweight and obese individuals. Int J Obes (Lond). 2005; 29:1308-1314.
21. Ardelt AA, McCullough LD, Korach KS, Wang MM, Munzenmaier DH, Hurn PD. Estradiol regulates angiopoietin-1 mRNA expression through estrogen receptor-alpha in a rodent experimental stroke model. Stroke. 2005;36:337-341.
22. Albrecht ED, Babischkin JS, Lidor Y, Anderson LD, Udoff LC, Pepe GJ. Effect of estrogen on angiogenesis in co-cultures of human endometrial cells and microvascular endothelial cells. Hum Reprod. 2003;18: 2039-2047.
23. Ye F, Florian M, Magder SA, Hussain SN. Regulation of angiopoietin and Tie-2 receptor expression in non-reproductive tissues by estrogen. Steroids. 2002;67:305-310.
24. Lim HS, Lip GY, Blann AD. Angiopoietin-1 and angiopoietin-2 in diabetes mellitus: relationship to VEGF, glycaemic control, endothelial damage/dysfunction and atherosclerosis. Atherosclerosis. 2005;180: 113-118.
25. Lim HS, Blann AD, Chong AY, Freestone B, Lip GY. Plasma vascular endothelial growth factor, angiopoietin-1, and angiopoietin-2 in diabetes: implications for cardiovascular risk and effects of multifactorial intervention. Diabetes Care. 2004;27:2918-2924.
26. Cai J, Kehoe O, Smith GM, Hykin P, Boulton ME. The angiopoietin/Tie-2 system regulates pericyte survival and recruitment in diabetic retinopathy. Invest Ophthalmol Vis Sci. 2008;49:2163-2171.
27. le Noble FA, Stassen FR, Hacking WJ, Struijker Boudier HA. Angiogenesis and hypertension. J Hypertens. 1998;16:1563-1572.
28. Nykanen AI, Krebs R, Saaristo A, Turunen P, Alitalo K, Yla-Herttuala S, Koskinen PK, Lemstrom KB. Angiopoietin-1 protects against the development of cardiac allograft arteriosclerosis. Circulation. 2003;107: 1308-1314.
29. Kim I, Moon SO, Park SK, Chae SW, Koh GY. Angiopoietin-1 reduces VEGF-stimulated leukocyte adhesion to endothelial cells by reducing ICAM-1, VCAM-1, and E-selectin expression. Circ Res. 2001;89: 477-479.
30. Lee JS, Song SH, Kim JM, Shin IS, Kim KL, Suh YL, Kim HZ, Koh GY, Byun J, Jeon ES, Suh W, Kim DK. Angiopoietin-1 prevents hypertension and target organ damage through its interaction with endothelial Tie2 receptor. Cardiovasc Res. 2008;78:572-580.
31. Fiedler U, Reiss Y, Scharpfenecker M, Grunow V, Koidl S, Thurston G, Gale NW, Witzenrath M, Rosseau S, Suttorp N, Sobke A, Herrmann M, Preissner KT, Vajkoczy P, Augustin HG. Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation. Nat Med. 2006;12:235-239.
32. Farhat N, Thorin-Trescases N, Voghel G, Villeneuve L, Mamarbachi M, Perrault LP, Carrier M, Thorin E. Stress-induced senescence predominates in endothelial cells isolated from atherosclerotic chronic smokers. Can J Physiol Pharmacol. 2008;86:761-769.
33. Dallabrida SM, Ismail NS, Pravda EA, Parodi EM, Dickie R, Durand EM, Lai J, Cassiola F, Rogers RA, Rupnick MA. Integrin binding angiopoietin-1 monomers reduce cardiac hypertrophy. FASEB J. 2008;22:3010-3023.
34. Wada H, Ono K, Satoh N, Kameda S, Shinjo D, Abe Y, Kawamura T, Morimoto T, Nakano T, Shimatsu A, Fujita M, Hasegawa K. Soluble Flk-1 and soluble Tie-2, endogenous inhibitors of endothelial cell-specific angiogenic signals, are increased in serum of patients with metabolic syndrome. Circulation. 2006;114:848.
35. Cao Y. Angiogenesis modulates adipogenesis and obesity. J Clin Invest. 2007;117:2362-2368.
36. Voros G, Maquoi E, Demeulemeester D, Clerx N, Collen D, Lijnen HR. Modulation of angiogenesis during adipose tissue development in murine models of obesity. Endocrinology. 2005;146:4545-4554.
37. Rupnick MA, Panigrahy D, Zhang CY, Dallabrida SM, Lowell BB, Langer R, Folkman MJ. Adipose tissue mass can be regulated through the vasculature. Proc Natl Acad Sci U S A. 2002;99:10730-10735.
38. Satchell SC, Harper SJ, Tooke JE, Kerjaschki D, Saleem MA, Mathieson PW. Human podocytes express angiopoietin 1, a potential regulator of glomerular vascular endothelial growth factor. J Am Soc Nephrol. 2002; 13:544-550.
39. Reungjui S, Roncal CA, Sato W, Glushakova OY, Croker BP, Suga S, Ouyang X, Tungsanga K, Nakagawa T, Johnson RJ, Mu W. Hypokalemic nephropathy is associated with impaired angiogenesis. J Am Soc Nephrol. 2008;19:125-134.
40. Villanueva S, Cespedes C, Vio CP. Ischemic acute renal failure induces the expression of a wide range of nephrogenic proteins. Am J Physiol Regul Integr Comp Physiol. 2006;290:R861-R870.
41. Morrow D, Cullen JP, Cahill PA, Redmond EM. Ethanol stimulates endothelial cell angiogenic activity via a Notch- and angiopoietin-1-dependent pathway. Cardiovasc Res. 2008;79:313-321.
42. Ward NL, Moore E, Noon K, Spassil N, Keenan E, Ivanco TL, LaManna JC. Cerebral angiogenic factors, angiogenesis, and physiological response to chronic hypoxia differ among four commonly used mouse strains. J Appl Physiol. 2007;102:1927-1935.
43. Imaizumi T, Yagihashi N, Kubota K, Yoshida H, Sakaki H, Yagihashi S, Kimura H, Satoh K. Expression of retinoic acid-inducible gene-I (RIG-I) in macrophages: possible involvement of RIG-I in atherosclerosis. J Atheroscler Thromb. 2007;14:51-55.
44. Ago T, Liu T, Zhai P, Chen W, Li H, Molkentin JD, Vatner SF, Sadoshima J. A redox-dependent pathway for regulating class II HDACs and cardiac hypertrophy. Cell. 2008;133:978-993.